GTx target after FDA blow

Memphis-based GTx may be an acquisition target, in the wake of an FDA adverse ruling on a clinical trial that sent its stock reeling. The CA reports. A fuller story also appears in today's Memphis Daily News. The situation vividly illustrates the type risks many Tennessee VCs say they can live without. MB Venture Partners exited the stock at its IPO in 2006.